title: [A case of advanced esophageal carcinoma with nephrotic syndrome completely responding to chemotherapy of docetaxel, nedaplatin and 5-fluorouracil].
abstract: A 78-year-old male was admitted to our hospital because of dysphagia. He had been diagnosed as nephritic syndrome at 30 years of age and had been treated with prednisolone 10 mg/day. Blood examination revealed renal dysfunction; BUN 25 mg/dL, Cr 1. 9 mg/dL, and glomerular filtration rate(GFR)47. 4 mL/min. Endoscopy showed a type 2 tumor at the middle thoracic esophagus, and the biopsy specimen revealed moderately differentiated squamous cell carcinoma pathologically. Computed tomography (CT) of the chest and abdomen showed no metastases at distant regions and lymph nodes. Clinical staging was Stage II (cT2cN0cM0). Because of old age and renal function, we chose chemotherapy using docetaxel, nedaplatin and 5-fluorouracil. The adverse event was grade 2 in leucopenia and grade 1 in inappetence, but the renal function did not progress. Repeated endoscopic examinations after chemotherapy revealed that the esophageal cancer was significantly reduced in size, and no cancer cells were pathologically detected by endoscopic biopsy, resulting in a complete response(CR). This chemotherapy of docetaxel, nedaplatin and 5-fluorouracil might be effective and tolerable for patients with renal dys- function due to nephritic syndrome.
authors.affiliation: Dept. of Surgery, Nippon Medical School Tama-nagayama Hospital, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matsutani
authors.forename: Eiji
authors.initials: E
authors.lastname: Uchida
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Seiji
authors.initials: S
authors.lastname: Suzuki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Maruyama
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Akira
authors.initials: A
authors.lastname: Matsushita
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hirakata
authors.forename: Masao
authors.initials: M
authors.lastname: Kawamoto
authors.forename: Hiroki
authors.initials: H
authors.lastname: Arai
authors.forename: Michinobu
authors.initials: M
authors.lastname: Umakoshi
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Wakabayashi
authors.forename: Koji
authors.initials: K
authors.lastname: Sasajima
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009404:Nephrotic Syndrome / Q000150:complications*; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D009944:Organoplatinum Compounds; D043823:Taxoids; D000077143:Docetaxel; C053989:nedaplatin; D005472:Fluorouracil